Lupin Partners with SteinCares for Marketing & Distribution of its Biosimilar roduct in Latin America

Mumbai based pharmaceutical major, Lupin Limited has announced a strategic licensing and supply partnership with SteinCares, a leading Latin American specialty healthcare company. The agreement applies to the commercialization of Lupin’s biosimilar ranibizumab in Latin America, excluding Mexico and Argentina.

Agreement Overview

Under the deal, SteinCares will lead the regulatory submission, product registration, and commercialization for ranibizumab throughout Latin America. Lupin will take care of manufacturing the drug.

Ranibizumab is a recombinant humanized monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A). It is used in the treatment of:

• Neovascular (wet) age-related macular degeneration (AMD)
• Macular edema following retinal vein occlusion (RVO)
• Diabetic macular edema (DME)
• Diabetic retinopathy (DR)
• Myopic choroidal neovascularization (mCNV)

Management Commentary

Dr. Cyrus Karkaria, President – Biotechnology, Lupin, said, “Our collaboration with SteinCares reflects our endeavour to bring cutting-edge, affordable healthcare solutions that address the critical needs of patients in LATAM. Our goal is to transform the landscape of the retinal industry in Latin America, We want to guarantee new cutting-edge therapies for patients and improve people’s quality of life.

Sebastián Katz, Chief Strategy Officer of SteinCares, said: “This strategic alliance with Lupin fortifies our portfolio, reaffirming SteinCares as a biosimilar hub powerhouse in the Latin American region. We are here, and we have helped these healthcare institutions achieve substantial cost savings based on our decades of experience and deep knowledge of healthcare in Latin America.

Strategic Significance

This collaboration is in line with Lupin’s aspirations to grow internationally and its commitment to providing access to high-quality, affordable biosimilar treatments. It also compliments SteinCares’ regional leadership in biosimilars and complex generics and enables both companies to make use of their strengths in manufacturing and regional distribution.

About Lupin Limited

• Lupin Limited serves over 100 markets globally and is recognized for its leadership in multiple therapeutic areas including respiratory, cardiovascular, anti-infective, and diabetes. The company operates 15 manufacturing sites and 7 research centers worldwide, employing over 23,000 professionals.
• SteinCares brings over four decades of healthcare expertise across 30+ countries in Latin America and the Caribbean, bridging global pharma innovations with regional healthcare access. This agreement marks a significant step in improving retinal healthcare access across Latin America while bolstering Lupin’s international biosimilar footprint.

Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/aedc7529-cd00-47f2-98e8-2eecc6001436.pdf